ENDPOINTS – Page 11 – Endpoints News

about the author

ENDPOINTS

editor@endpointsnews.com

author articles

LIB details Ph3 PCSK9 inhibitor data; Eyenovia seeks 'strategic alternatives'

Last year

Protara's $45M placement; Plus, news about Eupraxia and GenSight

Last year

Ascletis Pharma scraps liver disease program; Another reverse merger

Last year

Zymeworks removes CFO; Gilead extends Nurix deal

Last year

Bayer to cut 90 workers; Avalo's up to $185M private placement

Last year

Gamida Cell to go private; Stoke aims to raise $75M

Last year

Edgewood's $20M Series A; Nanoscope to pursue FDA approval for eye gene therapy later this year

Last year

Axsome clears Phase 3 in narcolepsy; Nkarta eyes $240M raise

Last year

Intellia exits hemophilia B pact with Regeneron; Sangamo targets $24M raise

Last year

Meiji Seika Pharma to supply Japan with self-amplifying mRNA Covid-19 vaccine in fall/winter of 2024

Last year

Nikkei Biotechnology

Innate ends Ph1b in peripheral T cell lymphoma; Layoffs at NextCure

Last year

Madrigal's $600M offering; PureTech to return $100M to shareholders

Last year

Bluebird's $175M loan; Spyre reveals second private placement

Last year

OcuTerra’s diabetic retinopathy drug fails PhII; Better Therapeutics to shut down

Last year

Regulus raises $100M; Cancer company files to go public

Last year

Lexeo brings in $95M; FDA lifts hold on Nurix cancer trial

Last year

Ultimovacs' melanoma vaccine fails in PhII; Regenxbio’s $140M offering

Last year

BridgeBio's $250M offering; ViiV's PhI data for ultra-long-acting HIV treatment

Last year

Viking's $350M offering; Baker Brothers leads another PIPE

Last year

Denali’s $500M placement; Brain health startup raises $26M

Last year

Merrimack to dissolve after recording $225M milestone; Cogent's $225M placement

Last year

Kura’s stock jumps on PhIb readout; FDA lifts hold on INmune Bio program; Nanobiotix’s $20M milestone

Last year

Merck inks deal with Unnatural Products; CG Oncology’s upsized IPO; Locus gets $24M from BARDA

Last year

Doudna’s new venture; Aclaris CEO to step down; Tome’s $114M liver disorder deal with Genevant

Last year

First page Previous page 8 9 101112 13 14 Next page Last page